LIDDS AB (publ) develops efficient drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and affect the patients’ quality of life. NanoZolid enables controlled, long-term and personalized release of the drug for up to six months. NanoZolid can be combined with traditional small molecules as well as with large biological molecules such as antibodies. LIDDS 17.35 -0.15 (-0.86%)Innovative drug delivery platform for the benefit of patients and pharma industry
Press releases
LIDDS’ NanoZolid® technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technolog LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue LIDDS receives patent approval in Europe Kommuniké från årsstämman i LIDDS
Invest in the future of
local cancer treatment
LIDDS (Local Intelligent Drug Delivery System) develops products based on a patented and clinically tested drug delivery technology. The unique properties of the pharmaceutical depot formulation is the basis for LIDDS technology platform for the development of new pharmaceutical products. LIDDS founded by researchers and entrepreneurs at Uppsala University, University of Gothenburg and the life science incubator PULS AB.
CEO STATEMENT
”The only company that develops effective and innovative local
oncology treatments with up to six months duration”
– Monica Walter, CEO
NanoZolid® – a unique proprietary technology
LIDDS has developed NanoZolid®, a proprietary technology that helps solve some of the main problems with the way drugs work in the body and affect the patients’ quality of life. NanoZolid retains the efficacy of the original drug compound but reduces the side effects. Frequent dosing and severe side effects can be avoided by delivering effective drugs locally to the disease area.
NanoZolid Portfolio
NZ-2HOF
Prostate cancer
Our most advanced project – Liproca® Depot for prostate cancer – makes it possible to inject a well-tested anti-hormonal drug, 2-hydroxyflutamide, directly into the tumor region.
NZ-DTX
Lungcancer & Solid tumors
Based on the NanoZolid® technology, LIDDS has successfully developed a new drug candidate in combination with docetaxel, one of the most commonly used drugs for cytostatic treatment of breast, prostate, head, neck, stomach and lung cancer.
NZ-DOX
Solid tumors
The NanoZolid®-technology works well for drug development in the treatment of diseases where there is a need for local, long-lasting effects and for minimizing side effects from potent drugs that are otherwise given in the form of an injection or tablets.
NZ-IO
Immunotherapy
Immuno-oncology is based on the principle of activating the body’s own immune system to attack cancer cells. However, with systemic immunotherapy the entire body is affected and serious side effects are common.
NanoZolid® - technology is widely applicable
LIDDS unique proprietary drug carriers can be used to develop new locally acting drugs for a wide range of cancers, such as tumors of the prostate, lung, ovarian, liver, brain, abdominal cavity, spine, head / neck, bone, uterus, kidney and bladder . Moreover, new treatments are developed to other intractable diseases that currently require systemic therapy to achieve high local drug concentrations. LIDDS has a unique and patented technology for local drug delivery that creates several advantages.
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2018-06-25 LIDDS’ NanoZolid® technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technolog
- 2018-06-07 LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue
- 2018-06-05 LIDDS receives patent approval in Europe
- 2018-05-16 Kommuniké från årsstämman i LIDDS
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
